Lantheus (LNTH) FY Conference Transcript
2025-06-10 19:40
Lantheus (LNTH) FY Conference June 10, 2025 02:40 PM ET Speaker0 Following session is not open to the press. Okay. Speaker1 Good afternoon, everyone. I'm Paul Choi, and I cover the biotechnology sector here at the firm at Goldman Sachs. It's my pleasure to welcome Lampius. Joining me on stage to my immediate left is Brian Markinson, CEO, and Bob Marshall to my far left. What I'll do is turn it over to Brian maybe for some introductory or overview comments and then we'll get into Q and A after that. Speaker0 ...
Erasca (ERAS) FY Conference Transcript
2025-06-10 19:40
Summary of Erasca (ERAS) FY Conference Call - June 10, 2025 Company Overview - **Company Name**: Erasca (ERAS) - **Mission**: Focused on eradicating RAS-driven cancers, which are mutated in approximately 30% to 50% of all diagnosed cancers annually [3][4] Key Programs - **Current Pipeline**: - **ERAS 15**: A pan RAS molecular glue, recently cleared IND [4][11] - **ERAS 4,001**: A pan KRAS inhibitor, also recently cleared IND [4][11] - **ERAS 12**: A bispecific antibody targeting EGFR, in earlier stages [5] Market Opportunity - **Unmet Need**: Millions of patients diagnosed annually with RAS mutant tumors, with 2.2 million for KRAS and 2.7 million including H and NRAS [7][38] - **Competitive Landscape**: - ERAS 15 has one main competitor, Revolution Medicine's RMC-6,236, but the space is relatively uncrowded due to chemistry and IP challenges [8][10] - The pan KRAS market is more competitive, but ERAS believes their program has a strong profile [8][10] Clinical Development Timeline - **IND Clearances**: Both ERAS 15 and 4,001 received IND clearances in May 2025, ahead of guidance [11][12] - **Phase I Data**: Expected in calendar year 2026 for both programs [12][37] - **Enrollment**: No concerns regarding enrollment due to high unmet need and interest from leading centers [38][39] Preclinical Data Highlights - **Binding Affinity**: ERAS 15 shows 8 to 20 times higher binding affinity to cyclophilin A compared to RMC-6,236 [14] - **In Vitro Potency**: 4 to 5 times greater potency than RMC-6,236 [15] - **Dosing**: Anticipated human dose for ERAS 15 to be about one-tenth of the comparator's dose, potentially leading to better tolerability [18][29] Safety and Efficacy Considerations - **Toxicity Monitoring**: Accumulation of the drug will be monitored, but no major concerns anticipated regarding drug-induced liver injury due to different binding mechanisms [30][31] - **Combination Therapies**: Plans to explore combinations with standard care agents, including cetuximab and PD-1 inhibitors [49][50] Financial Overview - **Licensing Agreements**: - ERAS 15: Upfront payment of $12.5 million, total deal value around $189 million [53] - ERAS 4,001: Upfront payment of $10 million, total deal value around $170 million [55] - **Cash Runway**: Extended guidance to the second half of 2028, providing over three years of cash [67] Strategic Focus - **Reprioritization**: Shifted focus from a pan RAF inhibitor (neparafenib) to RAS programs due to higher unmet needs and potential [59] - **Partnership Opportunities**: Open to finding strategic partners for neparafenib, with no rush to finalize a deal [63] Investor Sentiment - **Positive Feedback**: Investors have responded favorably to the strategic focus on RAS assets and extended cash runway [66][68] Conclusion - **Future Outlook**: Erasca is well-positioned with a strong pipeline and ample cash runway to advance its RAS programs, aiming to address significant unmet needs in oncology [73]
EyePoint Pharmaceuticals (EYPT) FY Conference Transcript
2025-06-10 19:40
EyePoint Pharmaceuticals (EYPT) FY Conference June 10, 2025 02:40 PM ET Speaker0 Good afternoon. Thanks for listening. My name is Jay Duker. I'm the president and CEO of EyePoint. I'd like to thank Goldman Sachs for inviting us to present today. And we are a publicly traded company, and I will be giving some forward looking statements. If you'd like our full legal disclaimers, I invite you to go to our website. EyePoint is the leader in sustained release drug delivery for retinal diseases. Our lead asset is ...
Vertex Pharmaceuticals (VRTX) FY Conference Transcript
2025-06-10 19:40
Vertex Pharmaceuticals (VRTX) FY Conference Summary Company Overview - Vertex Pharmaceuticals is focused on innovative therapies for cystic fibrosis (CF) and pain management, with recent launches including Gernavix for acute pain and Alevtrac for CF [1][33]. Key Industry Insights Product Launches and Pipeline - Vertex is concentrating on three major product launches: Gernavix, Alevtrac, and Kashyvi, with a strong pipeline that includes four programs in Phase III development [1][2]. - The company is also advancing programs like ADPKD in Phase II and Nav 1.7 for pain management [2]. Financial Guidance - Vertex raised its 2025 revenue guidance from $11.75 billion to $11.85 billion, indicating an 8% growth at the midpoint, primarily driven by the CF franchise [6][7]. - The company expects operational expenses (OpEx) to be between $4.9 billion and $5 billion for the year, with a slight increase anticipated in Q2 due to preparations for Phase III launches [11]. Market Dynamics and Policy Environment - Vertex has limited exposure to policy changes affecting Medicare and Medicaid, with approximately 9% exposure to Medicare and 23% to Medicaid for its CF franchise [12][13]. - The company is monitoring potential impacts from the No Pain Act, which aims to incentivize the use of non-opioid pain medications [42]. Product-Specific Insights Alevtrac Launch - Alevtrac is positioned to treat patients with ultra-rare mutations, with a broader label than Trikafta, potentially increasing patient uptake [18][19]. - The transition to Alevtrac is slower than expected due to increased liver monitoring requirements, which may deter some patients from switching from Trikafta [24][27]. Gernavix Launch - Early feedback on Gernavix has been positive, with broad physician writing across various settings and minimal barriers to access due to agreements with one of the three major pharmacy benefit managers (PBMs) [33][38]. - The company is optimistic about expanding Gernavix's use in hospitals, with some hospitals already adding it to their formularies [50]. Future Growth Opportunities Expansion into Chronic Pain - Vertex is pursuing a broad label for peripheral neuropathic pain (PNP), with ongoing discussions with the FDA regarding innovative approaches to clinical trials [44][46]. - The company aims to leverage its existing pain management products while exploring new indications [40]. Long-Term Potential - Vertex anticipates that Kashyvi will evolve into a multibillion-dollar product over time, with significant growth expected in the kidney disease segment [54][56]. - The company is also developing a type 1 diabetes program (VX-880) that could transform treatment for millions, with pivotal studies underway [61][68]. Conclusion - Vertex Pharmaceuticals is strategically positioned for growth through innovative product launches, a robust pipeline, and proactive engagement with regulatory bodies. The company is focused on maximizing the value of its therapies while navigating market dynamics and policy changes.
Thermon Group Holdings (THR) 2025 Conference Transcript
2025-06-10 19:30
Thermon Group Holdings (THR) 2025 Conference June 10, 2025 02:30 PM ET Speaker0 Okay. Speaker1 All right. Speaker0 Good afternoon. My name is Trip Caldwell with Wells Fargo on the banking side. Here today with Bruce Thames and Jan Schott, CEO and CFO respectively of Thermon Holdings. Thermon is a $1,000,000,000 market cap company that's focused on custom heating solutions for process industries. But maybe, Bruce, for those that are less familiar with Thermon, you can take us a layer deeper and talk a little ...
Capital One Financial (COF) 2025 Conference Transcript
2025-06-10 19:30
Capital One Financial (COF) 2025 Conference June 10, 2025 02:30 PM ET Speaker0 Alright, everybody. We're gonna get started. Before I get started, I'm just gonna read some disclosures. For important disclosures, see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosure. Taking of photographs and use of recording device is not allowed. If you have any questions, please reach out to your Morgan Stanley sales representative. So very excited to have Rich Fairbank and Jeff Norris ...
StepStone (STEP) 2025 Conference Transcript
2025-06-10 19:30
StepStone (STEP) 2025 Conference June 10, 2025 02:30 PM ET Speaker0 All right. We're going go ahead and get started here. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. Note that taking of photographs and use of recording devices is also not allowed. If you have any questions, please reach out to your Morgan Stanley sales representative. All right, great. With that out of the way, good afternoon, everyone. Thanks for staying wit ...
Riskified (RSKD) FY Conference Transcript
2025-06-10 19:02
Riskified (RSKD) FY Conference June 10, 2025 02:00 PM ET Speaker0 Well, you guys for showing up today. We have the pleasure of having Ito Gao from Riskified. And then for maybe those who don't know Riskified well, can Ito, could you maybe provide just a brief overview of what Riskified does? Speaker1 Sure. So we started by helping merchants manage ecommerce risk, looking at incoming transactions and understanding if they're fraudulent or not. And over the years, we've expanded to also helping them manage th ...
Immunome (IMNM) FY Conference Transcript
2025-06-10 19:02
Immunome (IMNM) FY Conference June 10, 2025 02:00 PM ET Speaker0 Good afternoon, everyone. Thank you so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. And really pleased to have with us Clay Siegel, who's the president and CEO of Immunome. So to start here, Clay, you formed this company. Maybe you could just level set for everyone in the room who isn't as familiar with regard to your strategy, your pipeline, and really the key focus points you want us to look at in the hal ...
Royalty Pharma (RPRX) FY Conference Transcript
2025-06-10 19:00
Royalty Pharma (RPRX) FY Conference June 10, 2025 02:00 PM ET Speaker0 Alright. We're just about at time. Let's get started with our next session. It's a pleasure to have the management team of Royalty Pharma here with us, Chris Hite, vice vice chairman and Ashwin Pai. Thank you for being here. Thank you. Welcome. So I guess, let's start high level. Can you maybe just start by framing Royalty Pharma for those of us who might not be that familiar with the story, provide a quick story of the sort of arc of th ...